Back to News
Market Impact: 0.35
BeOne Medicines AG Announces Third Quarter 2026 Financial Results and Raised Full Year Guidance
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
BeOne Medicines reported third-quarter 2026 global revenue of $1.9 billion, up 34% year over year. BRUKINSA sales were $1.4 billion, also up 34%; the available article text attributes the growth to U.S. sales but cuts off before providing further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
61600.70
More News
- Jefferies raises BeOne Medicines stock price target on solid quarter
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request